[ad_1]
This cohort study compares the bleeding risks among warfarin, rivaroxaban, and apixaban users in a national US cohort with atrial fibrillation and HIV.
[ad_2]
Source link
[ad_1]
This cohort study compares the bleeding risks among warfarin, rivaroxaban, and apixaban users in a national US cohort with atrial fibrillation and HIV.
[ad_2]
Source link